HeXun Biosciences Co., Ltd. (TPEX:6986)

HeXun Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	111.91	147.22	33.49	-5.19	-42.99
Depreciation & Amortization	27.91	23.52	19.1	14.19	11.43
Other Amortization	1.04	1.2	1.2	0.53	0.48
Loss (Gain) From Sale of Assets	1.62	0.01	0.05	-0.02	-0.2
Stock-Based Compensation	3.62	-	-	0.3	-
Other Operating Activities	-4.36	13.97	-0.07	-0.05	0.47
Change in Accounts Receivable	10.12	-62.39	-17.3	-4.98	-
Change in Inventory	9.56	-10.98	-4.6	-	-
Change in Accounts Payable	-1.07	1.81	-0.8	0.42	-4.3
Change in Unearned Revenue	5.26	6.97	-3.37	5.1	-
Change in Other Net Operating Assets	-1.71	-0.4	15.39	0.93	-0.39
Operating Cash Flow	163.89	120.92	43.09	11.23	-35.5
Operating Cash Flow Growth	35.54%	180.62%	283.77%	-	-
Capital Expenditures	-27.29	-37.29	-20.67	-1.23	-
Sale of Property, Plant & Equipment	-	-	-	0.13	8.84
Sale (Purchase) of Intangibles	-1.57	-	-0.64	-5.96	-
Investment in Securities	-129.43	-100	-	-72	-
Other Investing Activities	-0.09	-	-3.97	-	-35.78
Investing Cash Flow	-158.38	-137.29	-25.28	-79.05	-26.95
Long-Term Debt Repaid	-3.81	-40.31	-4.88	-2.46	-2.01
Net Debt Issued (Repaid)	-3.81	-40.31	-4.88	-2.46	-2.01
Issuance of Common Stock	-	-	125	105	78
Other Financing Activities	5.5	-	-	-	-0.2
Financing Cash Flow	1.69	-40.31	120.12	102.54	75.79
Net Cash Flow	7.21	-56.68	137.93	34.72	13.34
Free Cash Flow	136.61	83.63	22.42	10	-35.5
Free Cash Flow Growth	63.36%	272.98%	124.19%	-	-
Free Cash Flow Margin	46.59%	29.20%	17.17%	20.22%	-
Free Cash Flow Per Share	2.97	1.82	0.49	0.27	-1.16
Cash Interest Paid	1.1	1.24	1.79	1.64	1.57
Cash Income Tax Paid	18.33	0.17	-	-	-
Levered Free Cash Flow	94.91	33.7	9.68	0.46	-
Unlevered Free Cash Flow	95.61	34.43	10.84	1.48	-
Change in Working Capital	22.16	-64.99	-10.68	1.47	-4.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.